These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23909028)

  • 1. [Endocrinology of breast cancer as a heterogeneous disease: a decade after the millennium].
    Bershteĭn LM
    Vopr Onkol; 2013; 59(3):292-8. PubMed ID: 23909028
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
    Generali D; Berruti A; Foroni C; Bazzola L; Andreis D; Allevi G; Bersiga A; Dogliotti L; Fox SB; Harris AL; Bottini A
    J Natl Cancer Inst Monogr; 2011; 2011(43):67-70. PubMed ID: 22043044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Search for new treatments intensifies for triple-negative breast cancer.
    Brower V
    J Natl Cancer Inst; 2009 Nov; 101(22):1536-7. PubMed ID: 19880812
    [No Abstract]   [Full Text] [Related]  

  • 4. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Gene expression analysis and its clinical use in breast tumors].
    Semiglazov VF; Semiglazov VV; Moiseenko FV; Bogdanov AA; Boĭtsov VV; Viaz'min SV; Gorab DN; Chubenko VA; Brezhnev NV; Luk'ianchikova VS; Dubina MV
    Vopr Onkol; 2013; 59(1):25-9. PubMed ID: 23805447
    [No Abstract]   [Full Text] [Related]  

  • 6. [Triple-negative breast carcinoma--rewiev of current literature].
    Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
    Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel targets for triple-negative breast cancer.
    Carey LA
    Clin Adv Hematol Oncol; 2011 Sep; 9(9):678-80. PubMed ID: 22402512
    [No Abstract]   [Full Text] [Related]  

  • 8. What is triple-negative breast cancer?
    Irvin WJ; Carey LA
    Eur J Cancer; 2008 Dec; 44(18):2799-805. PubMed ID: 19008097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features.
    Venkitaraman R
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):199-207. PubMed ID: 20131996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Basal subtype of breast cancer--a unit of specific characteristics of immunophenotyping?].
    Niemiec J; Ryś J
    Pol J Pathol; 2011 Dec; 62(4 Suppl 4):s36-44. PubMed ID: 22693732
    [No Abstract]   [Full Text] [Related]  

  • 11. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer.
    Tang P; Wang J; Hicks DG; Wang X; Schiffhauer L; McMahon L; Yang Q; Shayne M; Huston A; Skinner KA; Griggs J; Lyman G
    Cancer Invest; 2010 Nov; 28(9):978-82. PubMed ID: 20690804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma.
    Sutton LM; Cao D; Sarode V; Molberg KH; Torgbe K; Haley B; Peng Y
    Am J Clin Pathol; 2012 Oct; 138(4):511-6. PubMed ID: 23010705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer.
    Andorfer CA; Necela BM; Thompson EA; Perez EA
    Trends Mol Med; 2011 Jun; 17(6):313-9. PubMed ID: 21376668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-negative breast cancer.
    Oncology (Williston Park); 2010 Oct; 24(10 Suppl):40a. PubMed ID: 21275325
    [No Abstract]   [Full Text] [Related]  

  • 15. Triple-negative breast cancer: what the radiologist needs to know.
    Whitman GJ; Albarracin CT; Gonzalez-Angulo AM
    Semin Roentgenol; 2011 Jan; 46(1):26-39. PubMed ID: 21134526
    [No Abstract]   [Full Text] [Related]  

  • 16. Receptor-based predictors of response in breast cancer.
    McGovern UB; Stebbing J
    Future Oncol; 2009 Apr; 5(3):283-6. PubMed ID: 19374534
    [No Abstract]   [Full Text] [Related]  

  • 17. Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?
    Arslan C; Isik M; Guler G; Kulac I; Solak M; Turker B; Ozisik Y; Altundag K
    Am Surg; 2012 Sep; 78(9):992-9. PubMed ID: 22964210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targets in triple negative breast cancer.
    O'Toole SA; Beith JM; Millar EK; West R; McLean A; Cazet A; Swarbrick A; Oakes SR
    J Clin Pathol; 2013 Jun; 66(6):530-42. PubMed ID: 23436929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of nuclear receptor DAX-1 and androgen receptor in human breast cancer.
    Chae BJ; Lee A; Bae JS; Song BJ; Jung SS
    J Surg Oncol; 2011 Jun; 103(8):768-72. PubMed ID: 21240988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.